Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.
2. Reismuller B, Attarbaschi A, Peters C, Dworzak MN, Potschger U, Urban C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group. Br J Haematol. 2009;144:559–70.
3. Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. Br J Haematol. 2018;180:82–9.
4. Kleinschmidt K, Kalwak K (chairs). Paed1 - ‘Paediatric Diseases Working Party Session’. In: 50th Annual Meeting of the EBMT. Glasgow, United Kingdom: EBMT; 2024.
5. Cheisa R. Paed1-3 - ‘Base edited CD7 CAR-T cell therapy in relapsed T-ALL’. In: 50th Annual Meeting of the EBMT; Glasgow, United Kingdom: EBMT; 2024.